Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

Abstract Background To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss target receptors and, as a result, only managed with chemotherapy. What is worse that TNBC frequently developing resistance to By using small interfering RNA (siRNA)-based therapeutics, our recent work demonstrated X-box-binding protein 1 (XBP1) was linked human epidermal growth factor receptor 2 positive (HER2+) development and chemoresistance. Given instability, off-target effects, net negative charge, hydrophobicity siRNA in vivo utilization clinical transformation, its use hampered. Thus, siRNA-based drug delivery system (DDS) ultra-stability specificity necessary address predicament delivery. Results Here, we assembled RNase resistant nanoparticles (NPs) based on 3WJ structure from Phi29 DNA packaging motor. improved targeted therapy sensitize chemotherapy, NPs were equipped an (EGFR) targeting aptamer XBP1 siRNA. We found could deplete expression suppress tumor after intravenous administration. Meanwhile, promote sensitization chemotherapy impede angiogenesis vivo. Conclusions The results further demonstrate serve effective promising platform not for but also chemotherapy-resistant therapy.